These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34479619)

  • 1. The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial.
    Huang J; Yu Y; Jiang Y; Chen W; Li Y; Shen Y; Zheng Q; Li H
    Trials; 2021 Sep; 22(1):585. PubMed ID: 34479619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of Naoxintong capsule for treating chronic stable angina: study protocol for a randomized controlled trial.
    Huanjia G; Hairong C; Jieqin Z; Xingzhen D; Xue F; Weizhang Z; Bojun C
    Trials; 2021 May; 22(1):336. PubMed ID: 33971940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
    J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT
    J Clin Psychiatry; 2013 Oct; 74(10):1010-7. PubMed ID: 24229754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.
    Zazula R; Husain MI; Mohebbi M; Walker AJ; Chaudhry IB; Khoso AB; Ashton MM; Agustini B; Husain N; Deakin J; Young AH; Berk M; Kanchanatawan B; Ng CH; Maes M; Berk L; Singh AB; Malhi GS; Dean OM
    Aust N Z J Psychiatry; 2021 Aug; 55(8):784-798. PubMed ID: 33092404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.
    Liebowitz MR; Yeung PP; Entsuah R
    J Clin Psychiatry; 2007 Nov; 68(11):1663-72. PubMed ID: 18052559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.